MedTrace Logo

Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML

NCT02229266 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-08-16

No results posted yet for this study

Summary

The trial investigates the efficacy of adoptive immunotherapy with haploidentical natural killer cells compared to standard chemotherapy (after first complete remission) in patients with a high-risk acute myeloid leukemia being older than 65 years of age and not eligible for allogeneic transplantation

Conditions

Interventions

BIOLOGICAL

NK cells

DRUG

Cytarabine

1 cycle of consolidation chemotherapy with high-dose cytarabine

Sponsors & Collaborators

  • German Research Foundation

    collaborator OTHER

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Martin Bornhäuser, Prof. Dr. med. · Universitätsklinikum Dresden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-04-22
Completion
2017-04-22

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02229266 on ClinicalTrials.gov